BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
DTSTART:20170326T030000
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3
TZNAME:CEST
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:20171029T020000
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10
TZNAME:CET
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20260428T111127Z
UID:57209db7e4dd9027089518@ist.ac.at
DTSTART:20170327T160000
DTEND:20170327T171500
DESCRIPTION:Speaker: Erik Sahai\nhosted by Daria Siekhaus\nAbstract: This 
 presentation will be split into two parts: the first will focus on cancer 
 cell invasion and the second part will investigate how the microenvironmen
 t contributes to therapy failure.\n\nCancer cells can use different migrat
 ory strategies\, particularly when challenged with complex three-dimension
 al matrices in vivo. It has recently become clear that collective cancer c
 ell invasion plays a key role in metastasis. We will present data on the m
 echanism of cooperation between epithelial cancer cells and stromal fibrob
 lasts. In particular\, analysis of a pathological heterotypic cell-cell co
 ntact will be presented.\n\nMany tumors show an initial response to target
 ed therapies before genetic resistance emerges\, however little is known a
 bout how tumor cells tolerate therapy before genetic resistance dominates.
  We present data that shows how the ECM generates a ‘safe haven’ in wh
 ich melanoma cells can tolerate targeted therapy.  This supports the popu
 lation of cancer cells from which genetically resistance emerges. Finally\
 , we present analysis of organ specific responses to targeted therapy in m
 elanoma.\n
LOCATION:Raiffeisen Lecture Hall\, Central Building\, ISTA
ORGANIZER:aeller@ist.ac.at
SUMMARY:Erik Sahai: Role of the microenvironment in cancer invasion and the
 rapy response
URL:https://talks-calendar.ista.ac.at/events/15
END:VEVENT
END:VCALENDAR
